“Immune mechanisms in fibrotic pulmonary sarcoidosis”. P. Weeratunga, D.R. Moller and L-P. Ho. Eur Respir Rev 2022; 31: 220178

The authors of this review, published in the December 2022 issue, requested to clarify the following sentences:

“This is an interesting finding as it matches the finding of type I IFN enrichment in IPF both in monocytes [50] and in a subset of macrophages (SPP1⁺ macrophages) [51]. Both of these findings have been associated with the extent of fibrosis in the lungs of IPF patients.”

The study cited as reference [51] reported that upregulation of type 1 IFN genes in SPP1⁺ macrophages was seen in systemic sclerosis associated interstitial lung disease patients, not IPF patients. As a result, this section of text has been corrected to read:

“This is an interesting finding as it matches the finding of type I IFN enrichment in IPF in monocytes [50] and in a subset of macrophages (SPP1⁺ macrophages) in systemic sclerosis associated interstitial lung disease patients [51]. Levels of monocytes were associated with extent of fibrosis in the lungs of IPF patients [50].”

The article has been corrected and republished online.

• Copyright ©ERS 2023